POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) |
|
|
| Recruiting | N/A | 5000 | Canada, US | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome | 05/24 | 07/24 | | |
COMMIT, NCT05702879: Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success |
|
|
| Recruiting | N/A | 240 | Europe | Ozanimod, TNF Inhibitor, infliximab, adalimumab, etanercept, golimumab, and certolizumab., Steroids, Prednisolon, Vedolizumab, Ustekinumab | Insel Gruppe AG, University Hospital Bern, Bristol-Myers Squibb | Ulcerative Colitis | 01/25 | 01/25 | | |
| Recruiting | N/A | 3500 | Europe | | Universitätsklinikum Hamburg-Eppendorf, Berufsverband der Deutschen Dermatologen e.V. (www.bvdd.de), Deutsche Dermatologische Gesellschaft e.V. (https://derma.de), AbbVie, Biogen, Janssen-Cilag G.m.b.H, medac GmbH, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, Pfizer Pharmaceuticals Ltd., Merck Serono GmbH, Germany, PsoNet.eu (http://www.psonet.eu/), Celgene, Eli Lilly and Company, Amgen, Almirall Hermal GmbH, UCB Pharma, Bristol-Myers Squibb, Viatris Inc., LEO Pharma | Psoriasis, Psoriatic-arthritis | 12/32 | 12/32 | | |
